TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02491827

Intervention type: OTHER
Intervention: Cellvizio mini laser probe
Description: Cellvizio mini laser probe is administered via the endoscopic device used during the neurosurgical procedures to provide the optical biopsy
Study: NCT03020264

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: glycemic sensor FREESTYLE Libre Pro
Description: Collection of hypoglycemia episodes with glycemic sensor FREESTYLE Libre Pro
Study: NCT04459494

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flapless implant surgery.
Description: Local anesthesia will be applied to the patients in the test group, and then the implant socket will be prepared without removing the flap and a dental implant will be placed.~Bite-wing film will be taken to control the implants in the same session after surgery, and patients will be given VAS (visual analog scale) to perform their assessment of pain on the 3rd day and 7th day. Patients will be given an appointment again after 3 months of treatment. In this session, implants will be evaluated with bite-wing film.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional implant surgery.
Description: Local anesthesia will be applied to the patients in the control group, and then the implant socket will be prepared after reflecting the flap and a dental implant will be placed.~Patients in the control group will receive a full thickness flap elevation and an implant socket will be prepared afterwards the implant will be placed and then the flap will be closed with 4-0 silk suture.~Bite-wing film will be taken from both groups to control the implants in the same session after surgery, and patients will be given VAS (visual analog scale) to perform their assessment of pain on the 3rd day and 7th day. Patients will be given an appointment again after 3 months of treatment. In this session, implants will be evaluated with bite-wing film.
Study: NCT02918955

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: up-front neck dissection
Study: NCT04538300

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Patient Satisfaction
Description: Patient satisfaction was questioned. Answers were recorded as one of the choices (never, sometimes, usually or always)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Patient Satisfaction
Description: Patient satisfaction was questioned. Answers were recorded as one of the choices (never, sometimes, usually or always)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Surgeon Satisfaction
Description: Surgeon satisfaction was questioned. Answers were recorded as one of the choices (never, sometimes, usually or always)

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Surgeon Satisfaction
Description: Surgeon satisfaction was questioned. Answers were recorded as one of the choices (never, sometimes, usually or always)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chewing Peppermint gum
Description: Peppermint gum was chewed for 15 minutes in patients with sufficient wakefullness.
Study: NCT02511795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: AZD1775 will be given twice daily (PO BID) over 3 days (6 doses) on Days 1-3 and 8-10 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.~Olaparib will be given orally BID on Days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: AZD1775 will be given twice daily (PO BID) over 3 days (6 doses) on Days 1-3 and 8-10 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.~Olaparib will be given orally BID on Days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: AZD1775 will be given twice daily (PO BID) over 5 days (10 doses) on Days 1-5 and 8-12 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.~Olaparib will be given orally BID on Days 1-14.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: AZD1775 will be given twice daily (PO BID) over 5 days (10 doses) on Days 1-5 and 8-12 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.~Olaparib will be given orally BID on Days 1-14.
Study: NCT03860831

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine + midazolam
Description: Group IN received intranasal midazolam (0.2 mg/kg) +ketamine (5mg/kg). Group IM received intramuscular midazolam (0.2 mg/kg) +ketamine (5mg/kg) in the gluteal region.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine + midazolam
Description: Group IN received intranasal midazolam (0.2 mg/kg) +ketamine (5mg/kg). Group IM received intramuscular midazolam (0.2 mg/kg) +ketamine (5mg/kg) in the gluteal region.
Study: NCT02918955

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: up-front neck dissection

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: 70 Gy in 35 fractions to the macroscopic disease 50 Gy in 25 fractions (if sequential boost) or 56 Gy in 35 fractions (if simultaneous integrated boost) to the elective volumes 66 Gy in 35 fractions to the post-operative region with lymphatic extracapsular extension (Arm B only)

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: 70 Gy in 35 fractions to the macroscopic disease 50 Gy in 25 fractions (if sequential boost) or 56 Gy in 35 fractions (if simultaneous integrated boost) to the elective volumes 66 Gy in 35 fractions to the post-operative region with lymphatic extracapsular extension (Arm B only)

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: 70 Gy in 35 fractions to the macroscopic disease 50 Gy in 25 fractions (if sequential boost) or 56 Gy in 35 fractions (if simultaneous integrated boost) to the elective volumes 66 Gy in 35 fractions to the post-operative region with lymphatic extracapsular extension (Arm B only)
Study: NCT04666142

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of the personal characteristics of the experimental and control groups
Description: General characteristics of the individuals in the experimental and control groups were compared.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of the personal characteristics of the experimental and control groups
Description: General characteristics of the individuals in the experimental and control groups were compared.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comparison of the personal characteristics of the experimental and control groups
Description: General characteristics of the individuals in the experimental and control groups were compared.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light applied experimental group, control group treated with standard intensive care lighting
Description: According to the results of randomization, the group to which the lighting system will be applied was assigned as experiment, and the group that will continue standard ICU lighting as control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light applied experimental group, control group treated with standard intensive care lighting
Description: According to the results of randomization, the group to which the lighting system will be applied was assigned as experiment, and the group that will continue standard ICU lighting as control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light applied experimental group, control group treated with standard intensive care lighting
Description: According to the results of randomization, the group to which the lighting system will be applied was assigned as experiment, and the group that will continue standard ICU lighting as control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light applied experimental group, control group treated with standard intensive care lighting
Description: According to the results of randomization, the group to which the lighting system will be applied was assigned as experiment, and the group that will continue standard ICU lighting as control

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light applied experimental group, control group treated with standard intensive care lighting
Description: According to the results of randomization, the group to which the lighting system will be applied was assigned as experiment, and the group that will continue standard ICU lighting as control
Study: NCT04475562

Intervention type: DEVICE
Group type: OTHER
Intervention: Aeonose
Description: All participants breathed through the Aeonose for five minutes. This device contains metal-oxide sensors that change in conductivity upon reaction with VOCs in exhaled breath. These conductivity changes are input data for machine-learning and used for pattern recognition. A nose clip was placed on the nose of each participant to avoid entry of non-filtered air in the device. Before measuring, the Aeonose was flushed with room air, guided through a carbon filter as well. During each measurement, a video was displayed to distract the participant and to reduce the chance of hyperventilation. Failed breath tests were excluded from analysis; the reason for failure was documented. Four similar Aeonose devices were used for breath analysis. A full-measurement procedure required sixteen minutes.
Study: NCT02526810

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin lispro
Description: continuous subcutaneous insulin injection( insulin lispro, Humalog) to reduce blood glucose in a certain level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Description: long-acting insulin injection with metformin hydrochloride, Glucophage and gliclazide modified release tablets, Diamicron MR to reduce blood glucose in a certain level
Study: NCT00924014

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conivaptan
Description: Conivaptan 20 mg IV bolus followed by a 4 hour infusion at 1.2 mg/hr

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Furosemide will be given IV at the subjects usual oral dose up to 80 mg. If the dose is 80 mg or more only 1/2 the dose will be given IV.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conivaptan and furosemide
Description: Furosemide bolus first; conivaptan 20 mg IV bolus/infusion at 1.2 mg/hour for a total of 4 hours
Study: NCT05286476

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Whole Body Vibration
Description: vibration was administered for 1min, with a rest interval of 1min between each vibration set repeating 10 vibrations, with a frequency of 30 Hz and an amplitude of 0-2 mm and a speed of 50 m /s,18 and these sessions lasted for 6 weeks 3 days a week. whole-body vibration was induced by a noninvasive oscillation platform

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pelvic floor exercises and static abdominal exercises in addition to diet instructions
Description: During the low abdominal hollowing with instructed pelvic floor co-contraction test subjects were instructed with the standard command: 'Breathing normally, and keeping your back still, gently lift and tighten your pelvic floor. Now gently draw in your low tummy as well and hold it'. Pelvic floor facilitates transversus abdominis thickness.~subject in supine lying with her arms crossed over the diastasis for support. And subject has to draw or pull the abdomen inwards so that there elicits an isometric contraction of abdominal muscles and repeated this for 5-7 times.

Intervention type: OTHER
Group type: OTHER
Intervention: pelvic floor exercises and static abdominal exercises in addition to diet instructions
Description: During the low abdominal hollowing with instructed pelvic floor co-contraction test subjects were instructed with the standard command: 'Breathing normally, and keeping your back still, gently lift and tighten your pelvic floor. Now gently draw in your low tummy as well and hold it'. Pelvic floor facilitates transversus abdominis thickness.~subject in supine lying with her arms crossed over the diastasis for support. And subject has to draw or pull the abdomen inwards so that there elicits an isometric contraction of abdominal muscles and repeated this for 5-7 times.
Study: NCT03989349

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nemolizumab
Description: Nemolizumab
Study: NCT02918955

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: 70 Gy in 35 fractions to the macroscopic disease 50 Gy in 25 fractions (if sequential boost) or 56 Gy in 35 fractions (if simultaneous integrated boost) to the elective volumes 66 Gy in 35 fractions to the post-operative region with lymphatic extracapsular extension (Arm B only)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy (Cisplatin)
Description: 100 mg/m2 every three weeks during radiotherapy~In Arm B, chemotherapy can be omitted in case of a cT1-2 primary and a surgical downstaged pN0-1 neck without lymphatic extracapsular extension.
Study: NCT04385316

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA extraction of samples and high-throughput sequencing of small panels
Description: DNA extraction of gastric tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA and tissue gDNA for the gene detection of gastric tumor.

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA extraction of samples and high-throughput sequencing of small panels
Description: DNA extraction of colorectal tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples and blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the two types of samples of the patients respectively, and the DNA sequencing results of the two types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA and tissue gDNA for the gene detection of colorectal tumor.

Intervention type: DIAGNOSTIC_TEST
Intervention: DNA extraction of samples and high-throughput sequencing of small panels
Description: DNA extraction of bladder tumor tissues and high-throughput sequencing of small panels were performed, and the relationship between the mutation spectrum of each sample and the corresponding patient clinical data (staging) was analyzed.~DNA extraction of tumer tissue samples ,urine sample，blood sample and high-throughput sequencing of small panels,DNA extraction and small panel sequencing were performed for the three types of samples of the patients respectively, and the DNA sequencing results of the three types of samples were compared, and the clinical data of the corresponding patients were referenced to evaluate the consistency of the results of peripheral blood ctDNA ,urine ctDNAand tissue gDNA for the gene detection of bladder tumor.
Study: NCT03375489

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth
Description: Teleconference meeting with the palliative care team. Palliative care is a medical specialty focused on lessening (or palliating) patients' symptoms and helping patients and their families cope with a serious illness

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In-person PC
Description: In person meeting with the palliative care team. Palliative care is a medical specialty focused on lessening (or palliating) patients' symptoms and helping patients and their families cope with a serious illness
Study: NCT02384044

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Crest® Sensi-Stop™ Strips

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Colgate® Sensitivity Relief Pen
Study: NCT03073317

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FullPIERS and sFlit/PLGF (Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio)
Description: Once the centre is randomised to receive the intervention, all eligible women will have serum sFlt1/PlGF measurement performed and fullPIERS assessment and both results will be revealed to the care providers. This will include all women with pre-eclampsia or suspected pre-eclampsia cared for at the main hospital centres (and not be limited to women referred to the hospital from the community health centres). sFlt-1/PlGF will be tested by immunoassays (Roche Platform®). The result read out is provided by specific machines provided by Roche in less than one hour, which permits rapid clinical decision-making. Risk stratification using fullPIERS will be performed on tablet computers using a pre-defined risk scoring system integrated within the MedSciNet database.
Study: NCT02353013

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplementation
Description: Standard fortification of human milk may not have enough protein for optimal growth of premature infants. The investigators will add extra protein to this group to increase the protein consumed.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard fortification
Description: Standard fortification of human milk involves adding a commercially available human milk fortifier to human milk in order to increase several nutrients.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard fortification
Description: Standard fortification of human milk involves adding a commercially available human milk fortifier to human milk in order to increase several nutrients.
Study: NCT04192669

Intervention type: DEVICE
Intervention: Heart rate monitoring
Description: The heart rate will be recorded and calculated by a heart rate monitor (Polar H10, Finland) located on the chest. The recording is done over a period of 5 minutes, the patient being in a sitting position, without any particular stimulus, in a quiet room. The recording is transferred via the HRV Logger application. Any ectopic beats and artifacts are automatically identified and replaced by values interpolated by the investigator, if necessary. The Kubios HRV Premium Software is used for all calculations.
Study: NCT00104728

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD1839
Study: NCT02918955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (Cisplatin)
Description: 100 mg/m2 every three weeks during radiotherapy~In Arm B, chemotherapy can be omitted in case of a cT1-2 primary and a surgical downstaged pN0-1 neck without lymphatic extracapsular extension.
Study: NCT02204046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIWA 4
Study: NCT01673854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Study: NCT01911650

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Platelet Rich Plasma
Description: This procedure will include a single collection of 35 mL of peripheral blood. A two-stage spinning protocol will be used: the 1st separates red blood cells from platelets, and the 2nd concentrates the platelets to yield approximately 4 mL of concentrated autologous platelet. This layer of platelet rich plasma will be placed in the syringe by the centrifuge machine.
Study: NCT02918955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy (Cisplatin)
Description: 100 mg/m2 every three weeks during radiotherapy~In Arm B, chemotherapy can be omitted in case of a cT1-2 primary and a surgical downstaged pN0-1 neck without lymphatic extracapsular extension.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy (Cisplatin)
Description: 100 mg/m2 every three weeks during radiotherapy~In Arm B, chemotherapy can be omitted in case of a cT1-2 primary and a surgical downstaged pN0-1 neck without lymphatic extracapsular extension.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early Salvage Neck Dissection in case of less than cCR (Arm A only)
Description: Early salvage neck dissection in case of residual lymph node disease will be performed based on the response evaluation by MRI and PET/CT performed 3 and 4 months after the end of (chemo)radiotherapy, respectively (and additional diagnostic modalities if clinically indicated by the physician) and not more than 3 weeks after this post-radiotherapy evaluation.~In Arm A, a successful early salvage neck dissection without the operation of the primary tumor in case of less than clinical complete response (cCR) will be considered a component of the multimodality treatment and not as a failure.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early Salvage Neck Dissection in case of less than cCR (Arm A only)
Description: Early salvage neck dissection in case of residual lymph node disease will be performed based on the response evaluation by MRI and PET/CT performed 3 and 4 months after the end of (chemo)radiotherapy, respectively (and additional diagnostic modalities if clinically indicated by the physician) and not more than 3 weeks after this post-radiotherapy evaluation.~In Arm A, a successful early salvage neck dissection without the operation of the primary tumor in case of less than clinical complete response (cCR) will be considered a component of the multimodality treatment and not as a failure.
Study: NCT04600843

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy with Patient education
Description: patient manual was translated and validated in Urdu which was provided to patients so that they can follow it at home

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy without patient Education
Description: Group B was only treated with proper physical therapy treatment protocol according to patient presenting condition
Study: NCT04155125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efepoetin alfa
Description: The administration interval and initial dosage for subjects who are randomly assigned to subcutaneous efepoetin alfa will be starting from 4 μg/kg BW once per 2 weeks, then titrated based on Hb level during study period.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mircera
Description: The starting dosage of Mircera arm will be 0.6 μg/kg BW per 2 weeks based on prior data in similar study populations with subsequent titration to achieve targeted Hb range. During the correction treatment period, the dosage of study drug will be adjusted to achieve a Hb level range within 10 - 12 g/dL and an increase ≥1.0 g/dL versus the individual patient's baseline Hb level. During the extension period, Hb levels should be maintained between 10 and 12 g/dL.